These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 27313263)
21. [Current antibiotic resistance profile of uropathogenic Escherichia coli strains and therapeutic consequences]. El Bouamri MC; Arsalane L; Kamouni Y; Yahyaoui H; Bennouar N; Berraha M; Zouhair S Prog Urol; 2014 Dec; 24(16):1058-62. PubMed ID: 25310915 [TBL] [Abstract][Full Text] [Related]
22. Clinical evaluation of guidelines and therapeutic approaches in multi drug-resistant urinary tract infections. Concia E; Bragantini D; Mazzaferri F J Chemother; 2017 Dec; 29(sup1):19-28. PubMed ID: 29271735 [TBL] [Abstract][Full Text] [Related]
23. Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option. Blondeau JM Drugs; 2004; 64(6):611-28. PubMed ID: 15018591 [TBL] [Abstract][Full Text] [Related]
24. Antimicrobial Resistance Trends of Milano A; Sulejmani A; Intra J; Sala MR; Leoni V; Carcione D Microb Drug Resist; 2022 Jan; 28(1):63-72. PubMed ID: 34520265 [TBL] [Abstract][Full Text] [Related]
25. Resistance trends in urinary tract pathogens and impact on management. Mazzulli T J Urol; 2002 Oct; 168(4 Pt 2):1720-2. PubMed ID: 12352343 [TBL] [Abstract][Full Text] [Related]
26. Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic Escherichia coli. Asadi Karam MR; Habibi M; Bouzari S Mol Immunol; 2019 Apr; 108():56-67. PubMed ID: 30784763 [TBL] [Abstract][Full Text] [Related]
27. Two Simple Rules for Improving the Accuracy of Empiric Treatment of Multidrug-Resistant Urinary Tract Infections. Linsenmeyer K; Strymish J; Gupta K Antimicrob Agents Chemother; 2015 Dec; 59(12):7593-6. PubMed ID: 26416859 [TBL] [Abstract][Full Text] [Related]
28. Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections. Chen YH; Ko WC; Hsueh PR Expert Opin Pharmacother; 2013 Apr; 14(5):587-96. PubMed ID: 23480061 [TBL] [Abstract][Full Text] [Related]
29. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. Hsueh PR; Hoban DJ; Carmeli Y; Chen SY; Desikan S; Alejandria M; Ko WC; Binh TQ J Infect; 2011 Aug; 63(2):114-23. PubMed ID: 21669223 [TBL] [Abstract][Full Text] [Related]
30. Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections. Carson C; Naber KG Drugs; 2004; 64(12):1359-73. PubMed ID: 15200349 [TBL] [Abstract][Full Text] [Related]
31. Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli. Ejrnæs K Dan Med Bull; 2011 Apr; 58(4):B4187. PubMed ID: 21466767 [TBL] [Abstract][Full Text] [Related]
32. Aspects of urinary tract infections and antimicrobial resistance in hospitalized urology patients in Asia: 10-Year results of the Global Prevalence Study of Infections in Urology (GPIU). Choe HS; Lee SJ; Cho YH; Çek M; Tandoğdu Z; Wagenlehner F; Bjerklund-Johansen TE; Naber K; J Infect Chemother; 2018 Apr; 24(4):278-283. PubMed ID: 29292177 [TBL] [Abstract][Full Text] [Related]
33. Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada--results of the CANWARD 2007-2009 study. Lagacé-Wiens PR; Simner PJ; Forward KR; Tailor F; Adam HJ; Decorby M; Karlowsky J; Hoban DJ; Zhanel GG; Diagn Microbiol Infect Dis; 2011 Mar; 69(3):314-9. PubMed ID: 21353959 [TBL] [Abstract][Full Text] [Related]
34. Oral fosfomycin for treating lower urinary tract infections due to multidrug-resistant Polat M; Ozkaya-Parlakay A; Tapısız A; Kara SS; Yüksel S J Chemother; 2022 Apr; 34(2):97-102. PubMed ID: 34286658 [TBL] [Abstract][Full Text] [Related]
35. Investigation of antibiotic resistance determinants and virulence factors of uropathogenic Escherichia coli. Sun DH; Lv DF; Mi ZH; Hu LQ; Huang Y; Gao X; Weng XB J Antibiot (Tokyo); 2020 May; 73(5):314-319. PubMed ID: 32076117 [TBL] [Abstract][Full Text] [Related]
36. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Wilson DT; May DB Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870 [TBL] [Abstract][Full Text] [Related]
37. Management of complicated urinary tract infections in the era of antimicrobial resistance. Bader MS; Hawboldt J; Brooks A Postgrad Med; 2010 Nov; 122(6):7-15. PubMed ID: 21084776 [TBL] [Abstract][Full Text] [Related]
38. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817 [TBL] [Abstract][Full Text] [Related]
39. Resistance Patterns of Escherichia coli in Women with Uncomplicated Urinary Tract Infection Do Not Correlate with Emergency Department Antibiogram. Hines MC; Al-Salamah T; Heil EL; Mallemat H; Witting MD; Johnson JK; Winters ME; Hayes BD J Emerg Med; 2015 Dec; 49(6):998-1003. PubMed ID: 26281821 [TBL] [Abstract][Full Text] [Related]